Ashwani Agarwal, MD
Hematology & Oncology · Dallas, TXNPI 1801837497
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Rigel Pharmaceuticals, Inc. at 26.5% of the total. Reporting peaked in 2019 at $80,329 and has fallen 77.3% since, to $18,234 in 2025. Among hematology & oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,371 payments — averaging $200.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rigel Pharmaceuticals, Inc.$73K
- AstraZeneca$30K
- Seagen Inc.$16K
- Dova Pharmaceuticals$16K
- Johnson & Johnson$10K
- Pfizer$10K
- plus $118K from 54 others
Across 1 payment — averaging $2650.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3K
What the payments were for
- Consulting fees$137,21850%
- Speaking & faculty fees$81,47330%
- Travel & lodging$26,30310%
- Food & beverage$29,45111%
- Education$7070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$275,152 in reported general payments places this provider in the 95th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 73 | $1,166,516 |
| XtandiEnzalutamide | 22 | $312,094 |
| Lenalidomide | 16 | $211,652 |
| BrukinsaZanubrutinib | 13 | $197,292 |
| KisqaliRibociclib Succinate | 14 | $193,899 |
| IbrancePalbociclib | 12 | $185,580 |
| NubeqaDarolutamide | 12 | $155,678 |
| EliquisApixaban | 91 | $78,903 |
| XareltoRivaroxaban | 47 | $38,279 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 94 | $3,932 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,650 |
| Anastrozole | 140 | $1,932 |
| Megestrol Acetate | 26 | $1,517 |
| Dexamethasone | 36 | $1,424 |
| Fentanyl | 12 | $1,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $396 | $1,166,51673 claims |
| Astellas Pharma US IncXtandi | $1,093 | $312,09422 claims |
| PfizerIbrance, Eliquis | $9,732 | $264,483103 claims |
| NovartisKisqali | $2,533 | $193,89914 claims |
| BayerNubeqa | $4,034 | $155,67812 claims |
| Johnson & JohnsonXarelto | $10,195 | $38,27947 claims |
| AstraZenecaSymbicort | $30,325 | $2,65011 claims |
| Lilly USA, LLCOlanzapine | $222 | $19520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Dallas
- Edward PearsonDallas$900K
- Christopher MaiselDallas$713K
- Katherine WangDallas$188K
- Houston HolmesDallas$178K
- Benjamin KitchensDallas$177K
- Farrukh AwanDallas$138K
- Dai Chu LuuDallas$90K
- Luis PineiroDallas$86K
- Joan SchillerDallas$85K
- Devesh PandyaHouston$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.